Healthcare Services

CRISPR and Cas gene market to reach $13.09B by 2030 at 22.3% CAGR

April 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Anticipated Rise In Market Value Of The CRISPR And Cas Gene Market During The Forecast Period?

The crispr and cas gene market size has seen significant expansion in recent years. It is anticipated to increase from $4.81 billion in 2025 to $5.86 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 21.8%. Historically, this expansion can be linked to the groundbreaking discovery of crispr cas systems, lower gene editing expenses, widespread adoption in academic research, the accessibility of research kits, and assistance from government funding.

The crispr and cas gene market is anticipated to experience rapid expansion over the coming years. Projections indicate it will reach $13.1 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 22.3%. This market’s growth during the projected timeframe is driven by factors such as the clinical application of gene editing, the broadening scope of personalized medicine, the emergence of new biotech startups, a rise in research funding, and improvements in delivery mechanisms. Significant trends anticipated for this period encompass the widening array of gene editing research applications, an increasing integration into cell line engineering, greater utilization in drug discovery processes, the creation of sophisticated crispr libraries, and the expansion of bespoke gene editing services.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/crispr-and-cas-gene-global-market-report

What Key Factors Are Affecting The CRISPR And Cas Gene Market Demand?

The increasing focus on personalized therapy is anticipated to boost the growth of the CRISPR and Cas gene markets in the future. Personalized therapy describes a medical approach that uses an individual’s genetic makeup to guide decisions regarding disease diagnosis, treatment, and prevention. CRISPR and the Cas gene, particularly Cas9, are utilized in personalized medicine, enabling precise modifications to a person’s genetic material and showing promise for breakthroughs in developing tailored therapies for genetic disorders, cancer, and various medical conditions. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based organization, reported that in 2023, the FDA approved 16 novel personalized therapies for rare disease patients, which is an increase from the six such treatments approved in 2022. Hence, the escalating demand for personalized therapy will propel the expansion of the CRISPR and Cas gene markets.

How Is The CRISPR And Cas Gene Market Broken Down By Segment Categories?

The crispr and cas gene market covered in this report is segmented –

1) By Product Type: Kits And Enzymes, Libraries, Design Tool, Antibodies, Other Products Types

2) By Service Type: Cell Line Engineering, gRNA Design, Microbial Gene Editing, DNA Synthesis

3) By Application: Clinical, Financial, Operational And Administrative

4) By End Use: Biotechnology And Pharmaceutical Companies, Academics And Government Research Institutes, Contract Research Organizations (CROs)

Subsegments:

1) By Kits And Enzymes: CRISPR Kits, Cas Enzymes, Grna Synthesis Kits

2) By Libraries: CRISPR Libraries For Gene Knockout, CRISPR Libraries For Gene Activation, Sgrna Libraries

3) By Design Tools: Online Design Platforms, Software For CRISPR Guide RNA Design, Custom Design Services

4) By Antibodies: Antibodies For Cas Proteins, Antibodies For Detection Of Edited Cells, Secondary Antibodies For Immunoassays

5) By Other Product Types: Delivery Systems, CRISPR-Related Consumables, Control Plasmids And Reagents

What Trends Are Influencing Changes In The CRISPR And Cas Gene Market?

Leading entities within the CRISPR and Cas gene markets are creating advanced products, including CRISPR-based cell-based gene therapy, to expand their product portfolios and secure a competitive edge. This therapy utilizes the CRISPR gene-editing technique to alter or mend genetic material inside cells, presenting a precise and potentially transformative method for addressing genetic disorders, illnesses, and various medical conditions directly at the cellular stage. An example of this is the approval granted by the U.S. Food and Drug Administration (FDA) in December 2023 to Vertex Pharmaceuticals Incorporated, a US-based biopharmaceutical firm, for CASGEVY (exagamglogene autotemcel [exa-cel]). CASGEVY functions as a CRISPR/Cas9 genome-edited gene therapy intended for managing sickle cell disease (SCD) in patients aged 12 and older experiencing repeated vaso-occlusive crises. This medicine represents an unprecedented class of treatment, holding the promise of a single, life-changing therapy for eligible sickle cell patients. Due to the specialized stem cell transplantation training required for CASGEVY administration, Vertex is partnering with proficient institutions to establish a network of independently operated, approved treatment centers (ATCs) throughout the United States, facilitating patient access to CASGEVY.

Which Players Are Present In The CRISPR And Cas Gene Market Space?

Major companies operating in the crispr and cas gene market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc, AstraZeneca plc, Danaher Corporation, Lonza Group AG, Bio-Rad Laboratories Inc., eGenesis, Novartis Institutes for BioMedical Research, GenScript, Takara Bio Inc., Merck KGaA, Horizon Discovery Group Plc, Beam Therapeutics Inc, Intellia Therapeutics Inc, New England BioLabs, Recursion Pharmaceuticals Inc, Caribou Biosciences Inc, Cellectis S.A., Editas Medicine Inc, CRISPR Therapeutics AG, Mammoth Biosciences, Inscripta Inc, Prime Medicine Inc, Precision BioSciences Inc, Sangamo Therapeutics Inc.

Get The Full CRISPR And Cas Gene Market Report:

https://www.thebusinessresearchcompany.com/report/crispr-and-cas-gene-global-market-report

Which Region Is The Leading Market For The CRISPR And Cas Gene Market?

North America was the largest region in the CRISPR and Cas gene market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the crispr and cas gene market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized CRISPR And Cas Gene Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/crispr-and-cas-gene-global-market-report

Browse Through More Reports Similar to the Global CRISPR And Cas Gene Market 2026, By The Business Research Company

Plant Breeding And Crispr Plants Market Report 2026

https://www.thebusinessresearchcompany.com/report/plant-breeding-and-crispr-plants-global-market-report

Crispr Gene Editing Market Report 2026

https://www.thebusinessresearchcompany.com/report/crispr-gene-editing-global-market-report

Crispr Technology Market 2026

https://www.thebusinessresearchcompany.com/report/crispr-technology-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795